Lamotrigine: pharmacokinetics
- PMID: 9429124
- DOI: 10.1177/0883073897012001041
Lamotrigine: pharmacokinetics
Abstract
The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The volume of distribution is between 1.25 and 1.47 L/kg and protein binding is about 55%. The half-life of lamotrigine is between 24.1 and 35 hours in drug naive adults but may be altered by enzyme inducing and inhibiting drugs. Clinical trials demonstrated no evidence of autoinduction or saturable metabolism. Younger children (0.17 to 5 years) eliminate lamotrigine faster than older children (5 to 10 years). Children may be more prone to enzyme induction than adults.
Similar articles
-
Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.Pharmacotherapy. 1999 Apr;19(4):437-41. doi: 10.1592/phco.19.6.437.31052. Pharmacotherapy. 1999. PMID: 10212015 Clinical Trial.
-
Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):1009-18. doi: 10.1517/17425255.2.6.1009. Expert Opin Drug Metab Toxicol. 2006. PMID: 17125413 Review.
-
Lamotrigine--a novel approach.Seizure. 1994 Dec;3 Suppl A:41-5. Seizure. 1994. PMID: 7894851 Review.
-
[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].Zhongguo Dang Dai Er Ke Za Zhi. 2008 Apr;10(2):105-9. Zhongguo Dang Dai Er Ke Za Zhi. 2008. PMID: 18433522 Chinese.
-
Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy.Epilepsy Res. 1991 Nov-Dec;10(2-3):191-200. doi: 10.1016/0920-1211(91)90012-5. Epilepsy Res. 1991. PMID: 1817959 Clinical Trial.
Cited by
-
Spotlight on lamotrigine in bipolar disorder.CNS Drugs. 2004;18(1):63-7. doi: 10.2165/00023210-200418010-00007. CNS Drugs. 2004. PMID: 14731061
-
Solubility of lamotrigine in age-specific biorelevant media that simulated the fasted- and fed-conditions of the gastric and intestinal environments in pediatrics and adults: implications for traditional, re-formulated, modified, and new oral formulations.BMC Biotechnol. 2023 Sep 8;23(1):36. doi: 10.1186/s12896-023-00809-2. BMC Biotechnol. 2023. PMID: 37684623 Free PMC article.
-
Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.Curr Pharmacol Rep. 2016 Dec;2(6):326-338. doi: 10.1007/s40495-016-0076-8. Epub 2016 Nov 8. Curr Pharmacol Rep. 2016. PMID: 28966903 Free PMC article.
-
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.Pharmacogenomics J. 2020 Dec;20(6):845-856. doi: 10.1038/s41397-020-0173-2. Epub 2020 Jun 2. Pharmacogenomics J. 2020. PMID: 32483200
-
Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.Acta Pharmacol Sin. 2012 Nov;33(11):1417-23. doi: 10.1038/aps.2012.118. Epub 2012 Oct 29. Acta Pharmacol Sin. 2012. PMID: 23103620 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical